TP53 and neoplasm: Because of the sustained expression of E6 and E7, HPV+ OPSCC require fewer somatic mutations to develop tumors [23–25], may not have developed the complement of mutations necessary for chemoradiation therapy resistance, and can still respond to treatment by activating p53, RB family members, and other interacting tumor suppressors [26].